NeuroFlow, a behavioral health technology company, has announced its acquisition of Alluceo, a behavioral health platform developed by Intermountain Health.
Alluceo, launched in 2018, is a team-based care platform designed to integrate mental and behavioral health into primary care. It facilitates team communication, risk and complexity assessments, and the delivery of coordinated care. NeuroFlow plans to integrate Alluceo’s capabilities into its analytics suite to enhance its ability to identify patient health risks.
This acquisition builds on the companies’ commercial partnership established last summer to bring behavioral health screening and analytics to primary care patients in Colorado. Intermountain Health aims to improve outcomes by proactively identifying patient health needs, a challenging task at scale. The integration of Alluceo will initially enhance NeuroFlow’s screening and assessments for Intermountain patients. The companies will continue to refine and test the model, with plans to eventually offer it to customers nationwide.
Intermountain’s risk model, developed over several years, combines behavioral and medical health data with clinical insights to provide a comprehensive view of patient health risks. It draws from multiple data sources, including patient self-reports, disease registries, electronic health records (EHRs), and claims data.
